secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2024-06-13T23:59:59+00:00
Accession:  0001104659-24-071249
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada Therapeutics shareholders approve officer liability limitation amendment and elect director
--------------------------------------------------------------------------------

- Stockholders approved Certificate of Amendment to limit officer liability as permitted by Delaware law.
- Gina Chapman elected as Class III director with 19,701,297 votes for, 101,960 withheld, 2,418,006 broker non-votes.
- Ernst & Young LLP ratified as independent auditor for FY 2024 (22,210,935 for, 2,174 against, 8,154 abstain).
- Certificate of Amendment filed with Delaware Secretary of State, effective June 13, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000110465924071249/0001104659-24-071249-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000110465924071249/tm2417220d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-071249

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer